Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

JNJ

Johnson & Johnson

Jun 12 • 04:00PM ET

156.66

Dollar change +1.40
Percentage change 0.90	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: MRK PFE NVS AMGN BMY LLY GSK ABT MDT SYK

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM IWD QUAL

Scroll to Statements

Index	DJIA, S&P 500	P/E	17.41	EPS (ttm)	9.00	Insider Own	0.14%	Shs Outstand	2.41B	Perf Week	1.95%
Market Cap	376.94B	Forward P/E	14.11	EPS next Y	11.10	Insider Trans	-0.60%	Shs Float	2.40B	Perf Month	5.54%
Income	21.81B	PEG	2.95	EPS next Q	2.68	Inst Own	73.52%	Short Float	0.80%	Perf Quarter	-3.88%
Sales	89.33B	P/S	4.22	EPS this Y	6.33%	Inst Trans	0.53%	Short Ratio	2.15	Perf Half Y	4.72%
Book/sh	32.47	P/B	4.82	EPS next Y	4.61%	ROA	11.93%	Short Interest	19.22M	Perf Year	6.48%
Cash/sh	16.12	P/C	9.72	EPS next 5Y	5.90%	ROE	29.45%	52W Range	140.68 - 169.99	Perf YTD	8.33%
Dividend Est.	5.14 (3.28%)	P/FCF	18.50	EPS past 5Y	0.55%	ROIC	18.73%	52W High	-7.84%	Beta	0.41
Dividend TTM	5.02 (3.20%)	Quick Ratio	1.03	Sales past 5Y	1.58%	Gross Margin	68.24%	52W Low	11.36%	ATR (14)	2.30
Dividend Ex-Date	May 27, 2025	Current Ratio	1.26	EPS Y/Y TTM	29.21%	Oper. Margin	23.83%	RSI (14)	57.30	Volatility	0.76% 0.77%
Employees	138100	Debt/Eq	0.67	Sales Y/Y TTM	-0.37%	Profit Margin	24.41%	Recom	2.20	Target Price	170.84
Option/Short	Yes / Yes	LT Debt/Eq	0.49	EPS Q/Q	238.80%	Payout	84.80%	Rel Volume	0.79	Prev Close	155.26
Sales Surprise	1.55%	EPS Surprise	7.33%	Sales Q/Q	2.39%	Earnings	Apr 15 BMO	Avg Volume	8.95M	Price	156.66
SMA20	1.87%	SMA50	1.74%	SMA200	0.19%	Trades		Volume	7,075,511	Change	0.90%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform	$200
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$173
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform	$180 → $183

Show Previous Ratings

Today 04:25AM	Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Stock Instead? (Motley Fool)
Jun-12-25 11:57AM	Kennedy Remakes CDC Committee in His Own Vaccine-Skeptical Image (Barrons.com)
11:00AM	New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia (PR Newswire)
05:40AM	J&Js Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial (Clinical Trials Arena)
Jun-11-25 04:45PM	Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit (Insider Monkey)
10:57AM	Loading…
10:57AM	Trump Wants Cheaper Drugs Like Europe Has. How It Works. (Barrons.com)
10:20AM	Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel (TipRanks)
09:50AM	Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term (Zacks)
09:36AM	JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects? (Zacks)
09:34AM	The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services (Zacks)
08:05AM	New data show TREMFYA (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis (PR Newswire)
07:00AM	Why defensive stocks could be your best bet in a wild market (Yahoo Finance Video)
06:20AM	Should You Invest in the Health Care Select Sector SPDR ETF (XLV)? (Zacks)
06:20AM	Should You Invest in the iShares U.S. Healthcare ETF (IYH)? (Zacks)
05:35AM	Johnson & Johnson MedTech introduces surgical stapler for tissue complexity (Medical Device Network)
05:00AM	Loading…
05:00AM	5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off (Motley Fool)
Jun-10-25 04:51PM	Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors (Business Wire)
04:25PM	Top Analyst Reports for Johnson & Johnson, T-Mobile US & Boeing (Zacks)
03:52PM	Fact Checking RFK Jr.'s Attack on Government Vaccine Experts (Barrons.com)
10:10AM	RFK Jr. removes CDC vaccine panel members: What to know (Yahoo Finance Video)
09:02AM	Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE? (Zacks)
06:20AM	Is WisdomTree U.S. LargeCap Dividend ETF (DLN) a Strong ETF Right Now? (Zacks)
Jun-09-25 11:33AM	Intuitive Surgical Stock Falls. The MedTech Company Gets Its First Sell Rating. (Barrons.com)
05:53AM	Judge rules J&J unit must pay $442M in antitrust case (MedTech Dive)
Jun-07-25 03:00PM	Corporate cash levels are starting to fall (Bloomberg)
05:59AM	Patents and economies of scale support Pfizer's wide moat (GuruFocus.com)
Jun-06-25 04:16PM	Challenges pharma companies face in push into US manufacturing (Yahoo Finance Video)
04:08PM	Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? (MarketWatch)
09:33AM	Intuitive Surgical Stock Gains 12.7% QTD: Is it Still a Buy Now? (Zacks)
07:39AM	3 Top Dividend Stocks Analysts Are Bullish on Right Now (MarketBeat)
09:00AM	Loading…
Jun-05-25 09:00AM	Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
05:00AM	J&J may take a softer tariff hit after US-China pause, CFO says (MedTech Dive)
04:48AM	Johnson & Johnson MedTech introduces automated system for surgical efficiency (Medical Device Network)
Jun-03-25 05:45PM	Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts (Zacks)
04:57PM	ASCO25: J&Js trispecific antibody shows 100% response in Phase I multiple myeloma study (Pharmaceutical Technology)
04:41PM	S&P 500 Gains & Losses Today: Dollar General Stock Soars as Discount Retailer Posts Solid Results (Investopedia)
11:02AM	5 Cheap Stocks to Buy in June (Motley Fool)
10:45AM	Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma (PR Newswire)
10:45AM	Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients (PR Newswire)
10:45AM	DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity (PR Newswire)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
08:00AM	Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC (PR Newswire)
06:41AM	J&J data support earlier use of combo pill in prostate cancer (BioPharma Dive)
04:00AM	How leading oncology drugmakers set the stage for future advances (Pharma Voice)
Jun-02-25 10:42AM	ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug (Clinical Trials Arena)
08:43AM	COO Q2 Earnings Signal Growth and Caution: How to Play the Stock? (Zacks)
08:23AM	'No more tears': Author Gardiner Harris on J&J's controversies over the years (CNBC TV)
May-30-25 08:18AM	J&J CEO Joaquin Duato on cancer treatments, M&A outlook and 'most favored nation' policy (CNBC TV)
May-29-25 12:53PM	HistoSonics histotripsy system receives early market access authorisation in UK (Medical Device Network)
11:53AM	ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study (Zacks)
06:21AM	3 Elite High-Yield Dividend Stocks Down 8% to 27% That Have Hiked Their Payouts for More than 50 Years in a Row (Motley Fool)
May-28-25 05:45PM	Johnson & Johnson (JNJ) Stock Moves -0.54%: What You Should Know (Zacks)
04:43PM	Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results (Business Wire)
10:08AM	Boston Scientific ends TAVR sales; J&J shares Monarch robot data (MedTech Dive)
May-27-25 11:19AM	TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock? (Zacks)
07:30AM	1 Top Dividend Stock to Buy for a Lifetime of Passive Income (Motley Fool)
May-25-25 07:07AM	US FDA Votes in Favor of Benefit-Risk Profile of Johnson & Johnson's DARZALEX FASPRO (Insider Monkey)
04:10AM	Investing for Passive Income? Here's What History Says About the Stability of Dividend King Stocks. (Motley Fool)
May-24-25 04:16AM	Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond (Motley Fool)
May-23-25 08:00AM	FDA Panel Reiterates the Cancer Risks of Talc (Business Wire)
06:20AM	Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now? (Zacks)
May-22-25 05:45PM	Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors (Zacks)
11:00AM	3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market (MarketBeat)
09:07AM	JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges (Zacks)
08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
05:20AM	Johnson & Johnson MedTech introduces ultrasound catheter for cardiac ablation (Medical Device Network)
May-21-25 04:40PM	Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference (Business Wire)
09:00AM	Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know (Zacks)
08:50AM	AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger (Zacks)
08:21AM	FDA panel backs Darzalex for early stage multiple myeloma (BioPharma Dive)
06:20AM	Should You Invest in the VanEck Pharmaceutical ETF (PPH)? (Zacks)
May-20-25 11:21PM	Johnson & Johnson (NYSE:JNJ) Hit with $147M Verdict in Landmark Antitrust Case Over Reprocessed Medical Devices (Insider Monkey)
06:21PM	U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma (PR Newswire)
12:24PM	Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts (Business Wire)
06:16AM	J&J subsidiary ordered to pay $147M for violating antitrust rules (MedTech Dive)
06:00AM	Companies Are Planning to Build Factories In America. Are Trump's Tariffs Working? (Investopedia)
May-19-25 12:09PM	Innovative Health awarded $147m in antitrust lawsuit against J&Js Biosense Webster (Medical Device Network)
09:08AM	Intravascular lithotripsy: market competition and clinical potential (Medical Device Network)
May-18-25 04:32PM	Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson's Biosense Webster Medical Technology Unit (Business Wire)
03:25PM	Dividend Hikes Offer Optimism Amid Tariff Turmoil (GuruFocus.com)
12:33PM	US States Likely to Defy US Downgrade to Keep Top Credit Ratings (Bloomberg)
May-17-25 12:20PM	Janssen-Cilags Tremfya approved by U.K.s MHRA for Crohns disease, UC (TipRanks)
09:30AM	Trump administration not backing down on Big Pharma pressure campaign (Yahoo Finance)
06:40AM	3 Magnificent Stocks That Are Passive Income Machines (Motley Fool)
May-16-25 03:08PM	Jim Cramer Notes That "People Are Staying Away From" Johnson & Johnson (Insider Monkey)
09:40AM	Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock (Zacks)
May-15-25 05:48PM	Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails (Business Wire)
11:30AM	Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report? (Zacks)
06:49AM	ISRG Stock Gains More than 8% YTD: Will the Uptrend Continue? (Zacks)
May-14-25 04:40PM	Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
11:00AM	Halozyme, J&J slide as analyst cuts rating on CMS draft guidance (TipRanks)
May-13-25 09:41PM	The Smartest Dividend Stocks to Buy With $5,000 Right Now (Motley Fool)
05:08PM	Is Johnson & Johnson (JNJ) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom? (Insider Monkey)
04:53PM	Big Pharma Counted on This Loophole. It May Be Closing. (Barrons.com)
04:18PM	Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News (Investor's Business Daily)
02:47PM	Big Pharma Counted on a Price Negotiation Loophole. It May Be Closing. (Barrons.com)
09:56AM	Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales (Zacks)
09:22AM	The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen (Zacks)
08:21AM	RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US (Zacks)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '25	Option Exercise	0.00	25,255	0	40,797	May 05 05:10 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	2,806	0	17,904	Feb 18 09:46 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '25	Option Exercise	0.00	1,029	0	15,501	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	1,765	0	15,111	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '25	Option Exercise	0.00	499	0	13,539	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '25	Sale	156.15	403	62,928	15,098	Feb 18 09:33 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '25	Option Exercise	0.00	607	0	91,037	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 14 '25	Option Exercise	0.00	7,367	0	96,674	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '25	Option Exercise	0.00	651	0	89,603	Feb 18 09:16 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '25	Option Exercise	0.00	1,971	0	6,113	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 14 '25	Option Exercise	0.00	19,330	0	20,661	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '25	Option Exercise	0.00	1,779	0	1,779	Feb 18 09:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '25	Option Exercise	0.00	1,350	0	15,927	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '25	Option Exercise	0.00	1,594	0	171,110	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 14 '25	Option Exercise	0.00	19,518	0	185,924	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '25	Option Exercise	0.00	1,302	0	167,221	Feb 18 09:08 PM
Swanson James D.	EVP, CIO	Feb 15 '25	Option Exercise	0.00	492	0	16,762	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 14 '25	Option Exercise	0.00	5,079	0	19,739	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 13 '25	Option Exercise	0.00	447	0	15,019	Feb 18 09:06 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '25	Option Exercise	0.00	419	0	13,095	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 14 '25	Option Exercise	0.00	2,608	0	14,576	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '25	Option Exercise	0.00	411	0	12,100	Feb 18 09:05 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 15 '25	Option Exercise	0.00	961	0	10,321	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 14 '25	Option Exercise	0.00	2,203	0	11,366	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '25	Option Exercise	0.00	651	0	8,991	Feb 18 09:03 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '25	Option Exercise	0.00	3,682	0	397,525	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 14 '25	Option Exercise	0.00	24,335	0	415,205	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '25	Option Exercise	0.00	3,470	0	392,498	Feb 18 09:02 PM
Decker Robert J	VP Corporate Controller	Feb 15 '25	Option Exercise	0.00	339	0	20,116	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 14 '25	Option Exercise	0.00	2,201	0	21,373	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 13 '25	Option Exercise	0.00	312	0	19,285	Feb 18 09:01 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '25	Option Exercise	0.00	492	0	21,839	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 14 '25	Option Exercise	0.00	4,740	0	24,591	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '25	Option Exercise	0.00	408	0	20,242	Feb 18 08:58 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 07 '25	Option Exercise	100.06	126,369	12,644,482	489,671	Feb 11 07:43 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 07 '25	Option Exercise	100.06	32,762	3,278,166	115,028	Feb 11 07:42 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 07 '25	Option Exercise	100.06	58,504	5,853,910	213,355	Feb 11 07:41 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Option Exercise	100.06	13,015	1,302,281	13,015	Feb 11 07:40 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Sale	153.89	13,015	2,002,878	0	Feb 11 07:40 PM
Wolk Joseph J	Officer	Feb 07 '25	Proposed Sale	153.89	13,015	2,002,924		Feb 07 01:27 PM
WEINBERGER MARK A	Director	Dec 12 '24	Buy	147.22	1,000	147,220	1,000	Dec 12 05:27 PM
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Option Exercise	100.06	5,635	563,838	24,608	Sep 03 04:48 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Sale	165.06	5,635	930,113	18,973	Sep 03 04:48 PM
Decker Robert J	Officer	Aug 30 '24	Proposed Sale	165.06	5,635	930,113		Aug 30 03:51 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Jul 08 '24	Option Exercise	0.00	9,809	0	24,852	Jul 09 05:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience